Amalgamated Bank Sells 783 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)

Amalgamated Bank cut its position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 11.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,909 shares of the company’s stock after selling 783 shares during the period. Amalgamated Bank’s holdings in Fulgent Genetics were worth $116,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in FLGT. Rhumbline Advisers raised its holdings in shares of Fulgent Genetics by 0.9% in the second quarter. Rhumbline Advisers now owns 68,210 shares of the company’s stock valued at $1,338,000 after acquiring an additional 637 shares in the last quarter. Signaturefd LLC lifted its position in shares of Fulgent Genetics by 103.6% in the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock worth $44,000 after purchasing an additional 1,132 shares during the period. Asset Dedication LLC bought a new position in shares of Fulgent Genetics during the second quarter valued at approximately $33,000. nVerses Capital LLC purchased a new position in Fulgent Genetics during the second quarter valued at approximately $43,000. Finally, CANADA LIFE ASSURANCE Co raised its stake in Fulgent Genetics by 11.0% in the first quarter. CANADA LIFE ASSURANCE Co now owns 29,103 shares of the company’s stock worth $631,000 after buying an additional 2,879 shares in the last quarter. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Fulgent Genetics news, CEO Ming Hsieh sold 2,313 shares of Fulgent Genetics stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total value of $52,805.79. Following the transaction, the chief executive officer now directly owns 707,275 shares of the company’s stock, valued at $16,147,088.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 4,324 shares of company stock worth $98,717 in the last 90 days. 31.76% of the stock is owned by corporate insiders.

Fulgent Genetics Trading Down 3.0 %

Shares of NASDAQ FLGT opened at $21.07 on Wednesday. Fulgent Genetics, Inc. has a 12-month low of $18.91 and a 12-month high of $30.68. The stock’s fifty day simple moving average is $22.77 and its two-hundred day simple moving average is $21.61. The stock has a market capitalization of $630.50 million, a PE ratio of -3.78 and a beta of 1.50.

Fulgent Genetics (NASDAQ:FLGT) last posted its earnings results on Friday, August 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.45. The company had revenue of $71.03 million for the quarter, compared to analyst estimates of $69.07 million. Fulgent Genetics had a negative return on equity of 2.75% and a negative net margin of 56.22%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.33) earnings per share. On average, equities analysts predict that Fulgent Genetics, Inc. will post -1.46 earnings per share for the current fiscal year.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.